Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (NGS Pre-sequencing, NGS Data Analysis), By Technology, By Application, By End Use, By Region, And Segment- Global Industry Analysis, Size, Share, Growth,

The global clinical oncology next generation sequencing market size was estimated at USD 787.91 million in 2023 and is projected to hit around USD 3,232.18 million by 2033, growing at a CAGR of 15.16% during the forecast period from 2024 to 2033.

Key Takeaways:

North America dominated the market in 2023 with a share of 49.68%
The Asia Pacific region is expected to expand at the fastest CAGR of 17.4% during 2024-2033
The targeted sequencing and resequencing segment held the largest market share of 73.17% in 2023
Whole-Genome Sequencing (WGS) is anticipated to be the fastest-growing segment with 17.5% CAGR from 2024 to 2032
The NGS sequencing segment accounted for the largest revenue share of 57% in 2023
Screening held the largest market share of 81.9% in 2023
The companion diagnostics segment is anticipated to witness the fastest CAGR of 20.9% from 2024 to 2033
The laboratories segment held the largest market share of 65.1% in 2023.
As an end-user, clinics are anticipated to register the fastest CAGR of 18.1% from 2024 to 2033.

Market Overview
The Clinical Oncology Next Generation Sequencing (NGS) market represents a transformative intersection of genomics and cancer care. Leveraging high-throughput sequencing technologies, NGS has revolutionized oncology by enabling precise, rapid, and cost-effective analysis of cancer-related genetic mutations. The role of NGS in clinical oncology has expanded significantly, evolving from a tool for academic research into a mainstay of precision diagnostics and therapeutic decision-making in real-world clinical settings.
In today’s personalized medicine era, cancer diagnosis and treatment are increasingly guided by molecular insights rather than solely histopathological evaluations. NGS facilitates detailed profiling of tumor DNA or RNA, enabling oncologists to detect somatic mutations, gene fusions, copy number variations, and epigenetic changes. This allows clinicians to tailor treatment strategies based on individual tumor biology, significantly improving outcomes in cancers such as non-small cell lung cancer (NSCLC), breast cancer, melanoma, and hematologic malignancies.
The adoption of NGS in clinical oncology is further propelled by its utility in non-invasive liquid biopsies, real-time tumor monitoring, and emerging applications like minimal residual disease (MRD) detection. As health systems strive for efficiency, accuracy, and personalized care, NGS stands at the forefront of diagnostic innovation in oncology, with vast untapped potential, particularly in emerging regions.
Major Trends in the Market

Widespread Integration of Liquid Biopsy with NGS: Non-invasive liquid biopsies are gaining popularity, especially in metastatic and recurrent cancer cases, enabling tumor profiling and monitoring through blood samples.

Rise in Companion Diagnostics Partnerships: Pharmaceutical and NGS companies are increasingly collaborating to develop companion diagnostics that match patients with the most effective targeted therapies.

Cost Reductions in Sequencing Technology: Continuous advances have significantly reduced the cost per genome, making clinical NGS more accessible to hospitals, labs, and patients.

Increased Use of AI in NGS Data Analysis: Artificial intelligence and machine learning algorithms are being used to interpret complex sequencing data, improving diagnostic accuracy and speed.

Commercialization of Pan-Cancer Panels: Comprehensive genomic profiling panels that assess hundreds of cancer genes are being launched for broad tumor profiling.

Regulatory Approvals and Reimbursement Expansion: Regulatory agencies like the FDA are approving more NGS-based oncology tests, and insurance coverage is improving, especially in North America and Europe.

Growth of Point-of-Care NGS Platforms: Development of compact, fast, and affordable sequencers for point-of-care settings is expanding NGS utility outside centralized labs.

Clinical Oncology Next Generation Sequencing Market Report Scope

Report Attribute
Details

Market Size in 2024
USD 907.36 million

Market Size by 2033
USD 3,232.18 million

Growth Rate From 2024 to 2033
CAGR of 15.16%

Base Year
2023

Forecast Period
2024 to 2033

Segments Covered
Technology, workflow, application, end use, region

Market Analysis (Terms Used)
Value (US$ Million/Billion) or (Volume/Units)

Report Coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Key Companies Profiled
Illumina, Inc.; Thermo Fisher Scientific; F. Hoffmann-La Roche Ltd.; Agilent Technologies; Myriad Genetics; Beijing Genomics Institute (BGI); Perkin Elmer; Foundation Medicine; Pacific Bioscience; Oxford Nanopore Technologies Ltd.; Paradigm Diagnostics; Caris Life Sciences; Partek, Inc.; Eurofins Scientific S.E.; Qiagen N.V.

Key Market Driver: Personalized Cancer Therapy
The most compelling driver of the Clinical Oncology NGS market is the growing demand for personalized cancer treatment. Traditional treatment paradigms based on cancer type and stage are being replaced by precision oncology approaches, where therapy is guided by molecular characteristics. NGS enables clinicians to identify specific genetic alterations such as EGFR mutations in lung cancer or BRCA mutations in breast and ovarian cancers that can be targeted by corresponding drugs.
For example, FoundationOne CDx and Oncomine Dx Target Test are FDA-approved NGS-based tests that help match patients with therapies like osimertinib, dabrafenib, and others. With more than 50 targeted cancer therapies requiring molecular profiling for eligibility, the clinical value of NGS is undeniable. Moreover, pharmaceutical companies now rely on NGS to recruit suitable patients for clinical trials, accelerating drug development and approval timelines.
Key Market Restraint: Data Interpretation and Infrastructure Challenges
Despite its benefits, one of the significant restraints in the clinical adoption of NGS is the complexity of data interpretation and the lack of standardized bioinformatics infrastructure. Unlike traditional diagnostic tests, NGS produces large volumes of raw data that require sophisticated tools and expertise for accurate interpretation. Misinterpretation can lead to misdiagnosis or inappropriate treatment decisions.
Moreover, not all healthcare institutions possess the infrastructure for storing, analyzing, and securing genomic data. The need for skilled personnel such as bioinformaticians and molecular pathologists, combined with the lack of interoperability between platforms, further complicates widespread clinical integration. This creates a gap between technological capability and real-world application, particularly in resource-limited settings.
Key Market Opportunity: Expansion into Emerging Markets
A significant opportunity for market expansion lies in the growing investment in oncology and genomic infrastructure in emerging markets. Regions such as Asia-Pacific and Latin America are increasingly investing in precision medicine programs, national genome projects, and healthcare digitization. This creates fertile ground for the adoption of NGS-based oncology solutions.
Countries like China and India have initiated large-scale cancer genomics projects aimed at cataloging mutations prevalent in their populations. With rising cancer incidence, growing health insurance coverage, and increasing availability of skilled medical professionals, these regions present a vast, underserved market. International companies are partnering with local labs and hospitals to establish sequencing facilities, deliver training, and introduce cost-effective panels tailored to regional needs.
Segmental Analysis
By Technology
Targeted Sequencing and Resequencing dominated the market by technology. This segment is favored due to its cost-effectiveness, quick turnaround times, and clinical relevance. Targeted panels focus on specific genes or regions known to be associated with cancer, enabling fast, high-depth analysis ideal for routine diagnostics. They are widely used for detecting actionable mutations, such as KRAS, BRAF, or ALK in solid tumors.
Whole Exome Sequencing (WES) is the fastest-growing segment. It allows broader insights by sequencing all protein-coding regions of the genome, uncovering both common and rare mutations. WES is increasingly used in research-heavy clinical settings and tertiary care centers for complex or rare cancers where targeted panels may miss novel or uncommon alterations. WES also provides valuable data for biomarker discovery and translational research.
By Workflow
NGS Pre-Sequencing was the dominant workflow segment. This stage includes critical processes such as sample collection, DNA extraction, library preparation, and target enrichment, which directly impact the accuracy and quality of results. Standardizing and optimizing pre-sequencing steps is essential for reliable data generation, and many providers now offer integrated kits to streamline this phase.
NGS Data Analysis is the fastest-growing workflow segment. The surge in sequencing throughput has created demand for robust bioinformatics pipelines and data interpretation tools. As AI and machine learning advance, real-time analysis, visualization dashboards, and cloud-based solutions are being increasingly adopted. These tools aid in transforming raw reads into clinically actionable insights, especially in hospitals and smaller labs lacking in-house expertise.
By Application
Companion Diagnostics dominated the application segment. These NGS tests are co-developed with targeted therapies to ensure patient suitability, minimizing adverse effects and enhancing treatment efficacy. For instance, patients with HER2-negative, PIK3CA-mutant breast cancer benefit from therapies like alpelisib, but only after being screened via companion diagnostics. The regulatory momentum around these tests is strong, with the FDA approving several in recent years.
Sporadic cancer screening is the fastest-growing subsegment. With increasing cases of spontaneous mutations leading to tumor development, especially in aging populations, NGS is being used to detect these de novo alterations. Routine use of tumor profiling in lung, colorectal, and prostate cancers is becoming standard practice, driving growth in this application area. Early-stage detection programs are incorporating sequencing-based diagnostics to improve prognoses.
By End-use
Hospitals dominate the clinical oncology NGS market by end-use. Due to their comprehensive patient volumes, multidisciplinary setups, and access to funding, hospitals are best positioned to adopt and implement NGS technologies. Academic and tertiary-care hospitals especially drive adoption by integrating sequencing into tumor boards, research initiatives, and personalized therapy programs.
Laboratories represent the fastest-growing end-use segment. Diagnostic labs, both standalone and those affiliated with larger health systems, are scaling up their capabilities to meet the rising demand for genomic testing. Many are offering outsourcing services to smaller clinics and hospitals, using automation and robotics to deliver rapid results. Commercial labs like Invitae and Caris Life Sciences have seen strong growth by providing flexible, scalable, and accredited NGS services.
By Regional Insights
North America, particularly the United States, remains the largest and most mature market for Clinical Oncology NGS. The region benefits from advanced healthcare systems, favorable reimbursement policies, robust regulatory frameworks, and strong investment in precision medicine. The presence of key players such as Illumina, Thermo Fisher Scientific, and Foundation Medicine ensures continual innovation and accessibility.
The U.S. Precision Medicine Initiative and national cancer genomics programs have accelerated clinical adoption. Furthermore, collaborations between academic institutions and commercial labs—like those between Dana-Farber Cancer Institute and Broad Institute support translational research and clinical applications. Reimbursement codes for NGS tests by CMS and private insurers have also broadened patient access.
Asia-Pacific is the Fastest-Growing Region
Asia-Pacific is witnessing the fastest growth due to a combination of rising cancer incidence, growing awareness, and expanding healthcare infrastructure. Countries such as China, India, Japan, and South Korea are investing heavily in cancer care facilities and genomic medicine programs. Initiatives like China’s National Genomics Data Center and India’s Genomics for Public Health project are laying the foundation for large-scale implementation of NGS.
Private players are also establishing sequencing labs and partnering with local healthcare providers. For instance, BGI in China and MedGenome in India are pioneering cost-effective sequencing tailored for regional genetic profiles. With favorable government policies, large populations, and increasing healthcare expenditure, Asia-Pacific presents a significant long-term growth opportunity.
Key Companies & Market Share Insights
Several small and mid-sized players are operating in the market. Companies involved in the market are adopting various strategies, such as the launch of innovative products, partnerships & collaborations, to maintain their market presence. For instance, in May 2023, Thermo Fisher Scientific collaborated with Pfizer to improve regional access to next-generation sequencing-based testing for breast and lung cancer patients in over 30 countries across Africa, the Middle East, Latin America, and Asia where developed genomic testing has earlier been confined or inaccessible. Some of the key players in the global clinical oncology next generation sequencing market include:

Illumina, Inc.
Thermo Fisher Scientific
F. Hoffmann-La Roche Ltd.
Agilent Technologies
Myriad Genetics
Beijing Genomics Institute (BGI)
Perkin Elmer
Foundation Medicine
Pacific Bioscience
Oxford Nanopore Technologies Ltd.
Paradigm Diagnostics
Caris Life Sciences
Partek, Inc.
Eurofins Scientific S.E.
Qiagen N.V.

Recent Developments

March 2025: Illumina launched a new high-throughput sequencer, NovaSeq X+, with applications tailored for oncology labs, providing ultra-fast whole genome and targeted cancer panel sequencing.

February 2025: Thermo Fisher Scientific announced an expansion of its Oncomine Precision Assay portfolio with a new liquid biopsy solution, enhancing non-invasive diagnostics for NSCLC and colorectal cancer.

December 2024: Foundation Medicine received FDA approval for its FoundationOne Tracker, a ctDNA-based MRD (minimal residual disease) monitoring assay for post-surgical cancer surveillance.

November 2024: Roche’s subsidiary, Flatiron Health, partnered with Guardant Health to integrate real-world genomic and clinical data, aiming to advance real-time decision-making in oncology.

October 2024: BGI and Japan’s National Cancer Center initiated a joint venture to sequence rare tumor genomes and develop region-specific companion diagnostics for targeted therapies.

Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Clinical Oncology Next Generation Sequencing market.
By Technology

Whole Genome Sequencing
Whole Exome Sequencing
Targeted Sequencing & Resequencing

By Workflow

NGS Pre-Sequencing
NGS Sequencing
NGS Data Analysis

By Application

Screening

Sporadic Cancer
Inherited Cancer

Companion Diagnostics
Other Diagnostics

By End-use

Hospitals
Clinics
Laboratories

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East & Africa (MEA) Show more